 Daxor Corporation NYSE MKT: DXR, an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced the first use of its BVA-100 test to guide volume treatment in a patient infected with the COVID-19 virus. The company also announced the release of a clinical protocol for fluid guidance when utilizing the BVA-100 diagnostic test for COVID-19 patients developed by leading medical experts. Optimal volume management and knowledge of capillary status is key to survivability, preventing collapse of the circulatory system and allowing time to defeat infection, said Michael Feldschuh, CEO of Daxor Corporation. 